These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28957559)

  • 21. A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China.
    Cheng H; Yan D; Zuo X; Liu J; Liu W; Zhang Y
    Pharmacogenet Genomics; 2018 May; 28(5):117-124. PubMed ID: 29642234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse Drug Reactions: An Evaluation Framework.
    Plumpton CO; Pirmohamed M; Hughes DA
    Clin Pharmacol Ther; 2019 Jun; 105(6):1429-1438. PubMed ID: 30466189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementing HLA-B*58:01 testing prior to allopurinol initiation in Malaysian primary care setting: A qualitative study from doctors' and patients' perspective.
    Ng WL; Hussein N; Ng CJ; Qureshi N; Lee YK; Kwan Z; Kee BP; Then SM; Abdul Malik TF; Mohd Zaidan FZ; Azmi SUF
    PLoS One; 2024; 19(1):e0296498. PubMed ID: 38206925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Febuxostat in the management of gout: a cost-effectiveness analysis.
    Smolen LJ; Gahn JC; Mitri G; Shiozawa A
    J Med Econ; 2016; 19(3):265-76. PubMed ID: 26535593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Personalized Medicine Approach to Guide Allopurinol Use and Prevent Serious Adverse Events: Ethnicity Is Not a Proxy for Genetics.
    Ikediobi O
    Clin Pharmacol Ther; 2021 Oct; 110(4):852-854. PubMed ID: 33330976
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost-Effectiveness of Colchicine Prophylaxis for Gout Flares When Commencing Allopurinol.
    Robinson PC; Dalbeth N; Donovan P
    Arthritis Care Res (Hoboken); 2021 Oct; 73(10):1537-1543. PubMed ID: 32558298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients.
    Presa M; Pérez-Ruiz F; Oyagüez I
    Clin Rheumatol; 2019 Dec; 38(12):3521-3528. PubMed ID: 31420811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
    Yu KH; Lai JH; Hsu PN; Chen DY; Chen CJ; Lin HY
    Scand J Rheumatol; 2016 Jul; 45(4):304-11. PubMed ID: 26771445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.
    Ko TM; Tsai CY; Chen SY; Chen KS; Yu KH; Chu CS; Huang CM; Wang CR; Weng CT; Yu CL; Hsieh SC; Tsai JC; Lai WT; Tsai WC; Yin GD; Ou TT; Cheng KH; Yen JH; Liou TL; Lin TH; Chen DY; Hsiao PJ; Weng MY; Chen YM; Chen CH; Liu MF; Yen HW; Lee JJ; Kuo MC; Wu CC; Hung SY; Luo SF; Yang YH; Chuang HP; Chou YC; Liao HT; Wang CW; Huang CL; Chang CS; Lee MT; Chen P; Wong CS; Chen CH; Wu JY; Chen YT; Shen CY;
    BMJ; 2015 Sep; 351():h4848. PubMed ID: 26399967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.
    Plumpton CO; Roberts D; Pirmohamed M; Hughes DA
    Pharmacoeconomics; 2016 Aug; 34(8):771-93. PubMed ID: 26984520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.
    Wu R; Cheng YJ; Zhu LL; Yu L; Zhao XK; Jia M; Wen CH; Long XZ; Tang T; He AJ; Zeng YY; Ma ZF; Zheng Z; Ni MZ; Cai GJ
    Oncotarget; 2016 Dec; 7(49):81870-81879. PubMed ID: 27835909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of HLA-B*58:01, the susceptible allele for allopurinol-induced hypersensitivity, by loop-mediated isothermal amplification.
    Kwok J; Kwong KM
    Br J Dermatol; 2013 Mar; 168(3):526-32. PubMed ID: 23066948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis.
    Jutkowitz E; Alarid-Escudero F; Choi HK; Kuntz KM; Jalal H
    Pharmacoeconomics; 2017 Oct; 35(10):1073-1085. PubMed ID: 28631197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How to prevent allopurinol hypersensitivity reactions?
    Stamp LK; Barclay ML
    Rheumatology (Oxford); 2018 Jan; 57(suppl_1):i35-i41. PubMed ID: 29272508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HLA-B*58: 01 carrier status of Hmong in Minnesota: first in Hmong genotyping for prevalence of this biomarker of risk for severe cutaneous adverse reactions caused by allopurinol.
    Peng K; Bjork J; Wen YF; Roman YM; Culhane-Pera K; Lo MX; Gertner E; Straka RJ
    Pharmacogenet Genomics; 2020 Feb; 30(2):21-25. PubMed ID: 31658186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of the HLA-B
    Park HW; Kim DK; Kim SH; Kim S; Chae DW; Yang MS; Oh YK; Lee JP; Jung JW; Shin J; Hwang JH; Kang MG; Kim SM; Kwon SK; Kim HY; Kim MH; Kim SJ; Ryu DR; Cho YJ; Jee YK; Kim SM; Lee EK; Kim JY; Cho HS; Jeong YY; Kim SH; Jun JB; Park JS; Kim GH; Kim S; Jung HY; Lee JM
    J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1271-1276. PubMed ID: 30580048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
    Smolen LJ; Gahn JC; Mitri G; Shiozawa A
    Clin Ther; 2016 Jul; 38(7):1710-25. PubMed ID: 27269247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.
    Kauf TL; Farkouh RA; Earnshaw SR; Watson ME; Maroudas P; Chambers MG
    Pharmacoeconomics; 2010; 28(11):1025-39. PubMed ID: 20575592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotyping HLA-B*5801 for Allopurinol-Induced Severe Cutaneous Adverse Reactions: An Accurate and Prompt Method.
    Cheng L; Zhang L; Gao L; Zhang W; Chen X; Zhou HH
    Clin Transl Sci; 2015 Dec; 8(6):834-6. PubMed ID: 26663557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.